These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1185 related articles for article (PubMed ID: 11742283)
1. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. Ruëff F; Wenderoth A; Przybilla B J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283 [TBL] [Abstract][Full Text] [Related]
2. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. Goldberg A; Confino-Cohen R J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360 [TBL] [Abstract][Full Text] [Related]
3. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Goldberg A; Yogev A; Confino-Cohen R Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964 [TBL] [Abstract][Full Text] [Related]
4. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Haeberli G; Brönnimann M; Hunziker T; Müller U Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741 [TBL] [Abstract][Full Text] [Related]
5. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy. Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233 [TBL] [Abstract][Full Text] [Related]
6. Possible circadian variation of serum mast cell tryptase concentration. Dugas-Breit S; Przybilla B; Schöpf P; Ruëff F Allergy; 2005 May; 60(5):689-92. PubMed ID: 15813817 [TBL] [Abstract][Full Text] [Related]
7. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187 [TBL] [Abstract][Full Text] [Related]
9. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250 [TBL] [Abstract][Full Text] [Related]
10. Bee venom immunotherapy - how early is it effective? Goldberg A; Confino-Cohen R Allergy; 2010 Mar; 65(3):391-5. PubMed ID: 19839973 [TBL] [Abstract][Full Text] [Related]
11. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. Lerch E; Müller UR J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496 [TBL] [Abstract][Full Text] [Related]
12. Deliberate hymenoptera sting challenge as a diagnostic tool in highly selected venom-allergic patients. Goldberg A; Confino-Cohen R; Mekori YA Ann Allergy Asthma Immunol; 1995 Jul; 75(1):30-2. PubMed ID: 7621057 [TBL] [Abstract][Full Text] [Related]
13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180 [TBL] [Abstract][Full Text] [Related]
14. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy. von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338 [TBL] [Abstract][Full Text] [Related]
16. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993 [TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy against hymenoptera venom: report of ten patients]. Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358 [TBL] [Abstract][Full Text] [Related]
18. Basophil sensitivity in patients not responding to venom immunotherapy. Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492 [TBL] [Abstract][Full Text] [Related]
19. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy]. Przybilla B; Ring J; Griesshammer B; Braun-Falco O Dtsch Med Wochenschr; 1987 Mar; 112(11):416-24. PubMed ID: 3816590 [TBL] [Abstract][Full Text] [Related]
20. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]